Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interrogation of a large clinical data cohort derived from a comprehensive panheme NGS-based assay for elucidation into MDS risk stratification, impact of chip on disease, biopsy sensitivity, and MRD evaluation

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSean T. Glenn

Discussion

Loading...

Member takes

Overview

Analysis demonstrates genomic alterations in myeloid malignancies, suggesting better monitoring with blood biopsies.

Key Points

  • To evaluate the impact of a PanHeme NGS assay on MDS risk stratification and disease monitoring.
  • Developed a Next-Generation Sequencing assay for hematological malignancies.
  • Interrogated a large clinical data cohort of over 4,000 patients and 6,000 tests.
  • Compared mutation calling between blood and bone marrow biopsies for concordance.
  • Identified over 46,000 NGS-based mutations across various hematological malignancies.
  • Demonstrated that the PanHeme assay accurately predicts survival in MDS without classical cytogenetics.
  • Developed a comprehensive MRD panel by assessing prevalent mutations in AML.

Cite This Study

Sean T. Glenn (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d918https://doi.org/10.1182/blood-2025-7384
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 4628: Validation of an automated, scalable comprehensive genomic profiling assay for hematologic malignancies2024 · 1 citations
  2. 2Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML2025
  3. 3How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know2025 · 1 citations
  4. 4Abstract 3663: Extending and analytical validation of a hematological cancer panel for simultaneous detection of driver mutations, copy number variations and translocations in tissue and blood samples2024
  5. 5Comparative Evaluation of Comprehensive DNA and RNA Sequencing Platforms with Subsequent Clinical Validation for Hematolymphoid Malignancies2026